816284--2/17/2009--CELGENE_CORP

related topics

{product, candidate, development}

{acquisition, growth, future}

{product, market, service}

{financial, litigation, operation}

{product, liability, claim}

{tax, income, asset}

{property, intellectual, protect}

{operation, international, foreign}

{control, financial, internal}

{condition, economic, financial}

{regulation, government, change}

{personnel, key, retain}

{provision, law, control}

{stock, price, share}

Sales of our products are dependent on third-party reimbursement. If we are unsuccessful in developing and commercializing our products, our business, financial condition, results of operations and liquidity could be materially adversely affected which could have a negative impact on the value of our securities. If our products are not accepted by the market, demand for our products will deteriorate or not materialize at all. The pharmaceutical industry is subject to extensive government regulation which presents numerous risks to us. We may not be able to protect our intellectual property and our products may be subject to generic competition. We have grown rapidly, and if we fail to adequately manage that growth our business could be adversely impacted. If the third parties upon whom we rely fail to produce on a timely basis the API, encapsulation, finishing and packaging services in the volumes that we require or fail to meet quality standards and maintain necessary licensure from regulatory authorities, we may be unable to meet demand for our products, potentially resulting in lost revenues. We utilize third parties for the distribution of our products in the U.S. We are continuing to establish foreign marketing and distribution capabilities. Certain risks related to the commercial success of VIDAZA may present significant challenges to us. The integration of entities we acquire may present significant challenges to us. We may be unable to retain skilled personnel and maintain key relationships. The hazardous materials we use in our research, development and other business operations could result in significant liabilities, which could exceed our insurance coverage and financial resources. Litigation on a variety of matters may subject us to significant legal expenses and liability. The pharmaceutical and biotech industry is highly competitive and subject to rapid and significant technological change. Changes in our effective income tax rate could impact our earnings. Our operations may be impacted by currency fluctuations that may cause our earnings to fluctuate. We may experience an adverse market reaction if we are unable to meet our financial reporting obligations. The current global credit and financial market conditions may exacerbate certain risks affecting our business. The price of our common stock may fluctuate significantly, which may make it difficult for you to sell the common stock when you want or at prices you find attractive. Our shareholder rights plan and certain charter and by-law provisions may deter a third-party from acquiring us and may impede the stockholders ability to remove and replace our management or board of directors.

Full 10-K form ▸

816284--2/17/2009--CELGENE_CORP_/DE/